Sphera Funds Management LTD. Acquires 11,175 Shares of Tesaro (TSRO)

Sphera Funds Management LTD. boosted its holdings in shares of Tesaro (NASDAQ:TSRO) by 11.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,175 shares of the biopharmaceutical company’s stock after buying an additional 11,175 shares during the period. Sphera Funds Management LTD. owned about 0.19% of Tesaro worth $6,067,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Gabelli Funds LLC boosted its stake in Tesaro by 49.0% during the first quarter. Gabelli Funds LLC now owns 14,900 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 4,900 shares in the last quarter. Bellevue Group AG boosted its stake in Tesaro by 100.8% during the first quarter. Bellevue Group AG now owns 144,802 shares of the biopharmaceutical company’s stock worth $8,274,000 after buying an additional 72,702 shares in the last quarter. Northern Trust Corp boosted its stake in Tesaro by 14.1% during the first quarter. Northern Trust Corp now owns 248,855 shares of the biopharmaceutical company’s stock worth $14,219,000 after buying an additional 30,828 shares in the last quarter. KBC Group NV boosted its stake in Tesaro by 56.6% during the first quarter. KBC Group NV now owns 8,781 shares of the biopharmaceutical company’s stock worth $502,000 after buying an additional 3,175 shares in the last quarter. Finally, EULAV Asset Management boosted its stake in Tesaro by 173.1% during the first quarter. EULAV Asset Management now owns 295,000 shares of the biopharmaceutical company’s stock worth $16,856,000 after buying an additional 187,000 shares in the last quarter.

A number of research firms have weighed in on TSRO. Citigroup decreased their price target on shares of Tesaro from $102.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday, May 4th. BidaskClub upgraded shares of Tesaro from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 6th. Credit Suisse Group reduced their target price on shares of Tesaro from $141.00 to $128.00 and set an “outperform” rating on the stock in a research note on Friday, May 4th. Bank of America reduced their target price on shares of Tesaro from $94.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, May 4th. Finally, Lake Street Capital restated a “buy” rating and issued a $80.00 target price (down previously from $120.00) on shares of Tesaro in a research note on Monday, May 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Tesaro has a consensus rating of “Buy” and an average target price of $119.00.

In other Tesaro news, CFO Timothy R. Pearson sold 2,575 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $54.86, for a total transaction of $141,264.50. Following the completion of the sale, the chief financial officer now directly owns 7,303 shares of the company’s stock, valued at approximately $400,642.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Orlando Oliveira sold 3,000 shares of the business’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $69.88, for a total value of $209,640.00. Following the sale, the senior vice president now directly owns 9,076 shares of the company’s stock, valued at $634,230.88. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. Insiders own 33.70% of the company’s stock.

Tesaro stock opened at $48.31 on Thursday. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.02 and a quick ratio of 3.56. Tesaro has a 12-month low of $44.76 and a 12-month high of $168.92. The stock has a market capitalization of $2.71 billion, a P/E ratio of -5.27 and a beta of 1.32.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.56) by ($0.42). Tesaro had a negative net margin of 193.42% and a negative return on equity of 177.92%. The business had revenue of $49.74 million during the quarter, compared to the consensus estimate of $56.34 million. During the same period in the prior year, the firm earned ($2.55) earnings per share. The business’s quarterly revenue was up 1520.2% compared to the same quarter last year. sell-side analysts predict that Tesaro will post -9.96 EPS for the current fiscal year.

About Tesaro

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tesaro (NASDAQ:TSRO).

Institutional Ownership by Quarter for Tesaro (NASDAQ:TSRO)

Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply